The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium: A Public–Private Collaborative Effort in Designing and Performing Clinical Trials for Novel Antibacterial Drugs to Prevent Nosocomial Pneumonia: Table 1.
Bruno François(Inserm), Hasan S. Jafri(AstraZeneca (Australia)), Marc J. M. Bonten(Utrecht University), P. Eggiman(University Hospital of Lausanne), Mark T. Esser(AstraZeneca (United States)), Antoní Torres(Centro de Investigación Biomédica en Red de Enfermedades Respiratorias), Miguel Sánchez(Stellenbosch University), Jean Chastre(Inserm), Herman Goosens(University of Antwerp), Brian Bishop, Pierre‐François Laterre(Cliniques Universitaires Saint-Luc)
Cited by 26
Related Papers
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k
Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal
|BMJ|2020|3.2k
A minimal common outcome measure set for COVID-19 clinical research
|The Lancet Infectious Diseases|2020|1.8k
International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia
|European Respiratory Journal|2017|1.4k
Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit
|The Lancet Respiratory Medicine|2014|1.3k